ArticleFrontiers in oncology2022

A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment.

Ja Min Byun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.